Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stevanato Group SpAMEX:STVN N 87 ROE % is 5.85% as of Jun. 2026, which is 61% below its 10-year median of 15.08. GuruFocus rates MEX:STVN N with a GF Score™ of 87/100 and a GF Value™ of MXN315.25. The stock has 6 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Stevanato Group SpA ranks better than 69.26% on this metric.
The historical rank and industry rank for Stevanato Group SpA's ROE % or its related term are showing as below:
MEX:STVN N'
s ROE % Range Over the Past 10 Years
Min: 9.12 Med: 15.08 Max: 28.4
Current: 9.12
During the past 8 years, Stevanato Group SpA's highest ROE % was 28.40%. The lowest was 9.12%. And the median was 15.08%.
MEX:STVN N's ROE % is ranked better than 69.26% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.75
vs MEX:STVN N: 9.12
Stevanato Group SpA (MEX:STVN N) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Stevanato Group SpA ROE % Related Terms
Stevanato Group SpA ROE % Historical Data
* Premium members only.
The historical data trend for Stevanato Group SpA's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's ROE % distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Stevanato Group SpA (MEX:STVN N) has a ROE % of 5.85% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Stevanato Group SpA and its competitors. This is 61% below median its historical median of 15.08. Over the past decade, Stevanato Group SpA's ROE % has ranged from 9.12 to 28.40. According to the industry distribution chart, Stevanato Group SpA ranks #245 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 30.7%.
Is Stevanato Group SpA's ROE % too high?
Stevanato Group SpA's current ROE % of 5.85% is 61% below median its 10-year median of 15.08. Over the past 10 years, this metric has ranged from a low of 9.12 to a high of 28.40. The Medical Devices & Instruments industry median ROE % is 2.75. Stevanato Group SpA's value of 5.85% is 112.7% above this industry median. Based on the distribution chart, Stevanato Group SpA ranks #245 out of 797 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stevanato Group SpA has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's ROE % compare to MMED and TFX?
According to the Medical Devices & Instruments industry distribution chart, Stevanato Group SpA ranks #245 out of 797 companies for ROE %. This puts Stevanato Group SpA in the upper half of its industry. The industry median ROE % is 2.75. Stevanato Group SpA's value of 5.85% is 112.7% above this benchmark. Historically, Stevanato Group SpA's own ROE % has ranged from 9.12 to 28.40 over the past decade. While the company's 10-year median is 15.08 vs. the industry median of 2.75, Stevanato Group SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.75, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stevanato Group SpA's current ROE % of 5.85% is 112.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Stevanato Group SpA and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stevanato Group SpA's current ROE % is 5.85%, which is 61% below median its own 10-year median of 15.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Stevanato Group SpA (MEX:STVN N) has a current ROE % of 5.85%. The stock's GF Value™ is MXN315.25, compared to a current price of MXN246.00 — trading 22% below its estimated fair value. The current ROE % is 5.85%, which is 61% below median its 10-year median of 15.08 and 112.7% above the Medical Devices & Instruments industry median of 2.75. Stevanato Group SpA's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Stevanato Group SpA (MEX:STVN N), the current ROE % is 5.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (MEX:STVN N) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of MXN246.00 is trading 22% below its estimated GF Value™ of MXN315.25.
Key valuation signals for MEX:STVN N:
ROE %: 5.85% (61% below median its 10-year median of 15.08)
GF Value™: MXN315.25 vs. price of MXN246.00 (22% below fair value)
Industry Position: 112.7% above the Medical Devices & Instruments median (#245 of 797)
No single metric tells the full story. See the MEX:STVN N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
87GF Score
Get the complete analysis for MEX:STVN N
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:STVN N has been successfully added to your 
